Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

5AM incubator spinout Homology raises $43.5M

Written by LVS on in the category news with the tags .


Gene editing company Homology Medicines Inc. spun out of 5AM Ventures' incubator with a $43.5 million series A round led by 5AM and Arch Venture Partners. Temasek, Deerfield and Arch Overage Fund also participated.

Homology's platform uses adeno-associated viral (AAV) vectors derived from CD34+ hematopoietic stem cells (HSCs) to induce gene editing through homologous recombination. The newco plans to use the platform for therapeutic in vivo gene editing, with an initial focus on rare monogenic diseases including hemoglobinopathies, inborn errors of metabolism and CNS disorders.

Homology has an exclusive, worldwide license to the platform and vectors from the lab of Saswati Chatterjee, the company's scientific founder and a professor of virology at the Beckman Research Institute of City of Hope. The company's management team includes President and CEO Arthur Tzianabos, formerly president and CSO of OvaScience Inc. (NASDAQ:OVAS); COO Sam Rasty, who was VP and head of new products in the rare diseases business unit of Shire plc (LSE:SHP; NASDAQ:SHPG); and CSO Albert Seymour, who was Shire's SVP and global head of research and nonclinical development. 5AM's Kush Parmar and Arch's Steven Gillis joined Homology's board.

Adapted from BioCentury

Read more about: .

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

V-Bio Ventures Biowin Itera Life Science Flanders.bio UGent XpandInnovation Janssen KU Leuven Turnstone GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.